You are here: Industry Insights > GPCR

News List

Sosei Heptares and Verily to collaborate on immune-mediated disease treatments pharmatimes
January 06, 2022
The companies share the goal of furthering knowledge around GPCR biology in immune cells in order to better understand a range of immune system disorders.
VERAXA Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs b3cnewswire
August 11, 2021
VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, announced today their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for colorectal cancer.
Orion Biotechnology Secures $11.5M Series A Financing firstwordpharma
June 24, 2021
Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company, today announced that it has raised $11.5M USD in a Series A financing.
Eurofins Scientific Acquires Beacon Discovery contractpharma
February 20, 2021
Eurofins Scientific, a leader in bioanalytical testing, has acquired Beacon Discovery, a preeminent drug discovery and contract research organization (CRO) focused on G-Protein Coupled Receptor (GPCR) research.
Orion Biotechnology Project Awarded Grant to Advance Drug Discovery americanpharmaceuticalreview
January 21, 2021
Orion Biotechnology announced its drug discovery project was awarded funding of CHF 0.9M from Innosuisse, the Swiss Innovation Agency.
Velabs Therapeutics Enters into a Screening Cooperation with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening After b3cnewswire
August 30, 2019
Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, today announced that its cooperation with Chiome Bioscience, Inc., Tokyo, will be deepened...
Sosei Heptares, Genentech Announces Research, License Agreement americanpharmaceuticalreview
July 17, 2019
Sosei Group has entered into a multi-target research collaboration and license agreement with Genentech, a member of the Roche Group, to discover and develop novel medicines (new small molecules and/or biologics) that modulate G protein-coupled receptor (
Confo Therapeutics and DyNAbind to Collaborate on Drug Discovery contractpharma
July 04, 2019
Aims to identify novel small molecule GPCR-modulating compounds.
Confo Therapeutics and DyNAbind Announce Drug Discovery Collaboration to Identify Novel GPCR-Modulating Compounds b3cnewswire
July 03, 2019
Confo Therapeutics and DyNAbind Announce Drug Discovery Collaboration to Identify Novel GPCR-Modulating Compounds.
Velabs Therapeutics to Cooperate with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening b3cnewswire
April 25, 2019
Velabs Therapeutics to Cooperate with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening.

Previous page 1 2 Next page